CELC Stock — Celcuity Inc.

Celcuity Inc. (CELC)

Updated October 16, 2026.

CELC is a Stock. Total return is 295.9% over the past 9.1 years, 45.6 points ahead of SPY at 250.3%.

Celcuity Inc. is a clinical-stage biotechnology company developing targeted therapies for solid tumors, with its lead candidate Gedatolisib in development for hormone receptor positive breast cancer and metastatic castration resistant prostate cancer under a license agreement with Pfizer. The company does not currently have an established distribution schedule. This security appeals to investors with a high risk tolerance seeking exposure to early-stage oncology drug development.

CELC performance versus SPY

Price and return data through 2026-10-16.

Total return is 295.9% over the past 9.1 years, 45.6 points ahead of SPY at 250.3%. Over the past year its total return — price change plus distributions reinvested — is 7.7%. Its deepest 1-year drawdown was 61.0%.

CELC key facts

Asset type

Stock

Asset class

Equity

Inception date

09/20/2017

Distribution frequency

None

Last close

$56.58 (as of 2026-10-16)

Market cap

$2,768,567,355

Average volume

4338226.0

Beta

0.108

Payout ratio

0.0%

EPS

$-4.31

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CELC risks and drawbacks

The deepest 1-year drawdown on record here is 61.0%.

Who may consider CELC — and who may not

It is a weaker fit for investors who need monthly cash flow (CELC does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on CELC

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions